NASDAQ : APVO
Aptevo Therapeutics Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 1.34 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 2.41M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 3.70M |
| Enterprise Value | -1.88M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 2.67M |
| Shares Outstanding | 2.67M |
| Shares Change (YoY) | +7,302.27% |
| Shares Change (QoQ) | +12.79% |
| Owned by Insiders (%) | 0.25% |
| Owned by Institutions (%) | 3.73% |
| Float | 2.56M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.31 |
| P/TBV Ratio | 0.59 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 2.08 |
| Quick Ratio | 1.89 |
| Debt / Equity | 0.70 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -420.34% |
| Return on Assets (ROA) | -111.49% |
| Return on Invested Capital (ROIC) | -154.28% |
| Return on Capital Employed (ROCE) | -288.14% |
| Weighted Average Cost of Capital (WACC) | 6.19% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$803,182 |
| Employee Count | 33 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 1.68 |
| 52-Week Price Change | -95.02% |
| 50-Day Moving Average | 1.83 |
| 200-Day Moving Average | 4.33 |
| Relative Strength Index (RSI) | 31.36 |
| Average Volume (20 Days) | 45,342 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 96,527 |
| Short Previous Month | 119,457 |
| Short % of Shares Out | 3.62% |
| Short % of Float | 3.77% |
| Short Ratio (days to cover) | 1.60 |
Incomestatement
| Measure | Value |
|---|
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -26.89M |
| Pretax Income | -26.41M |
| Net Income | -26.51M |
| EBITDA | -26.69M |
| EBIT | -26.89M |
| Earnings Per Share (EPS) | -$29.72 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 9.80M |
| Total Debt | 4.21M |
| Net Cash | 5.59M |
| Net Cash Per Share | $2.10 |
| Equity (Book Value) | 6.04M |
| Book Value Per Share | 4.26 |
| Working Capital | 5.61M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -25.34M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 197,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -25.34M |
| FCF Per Share | -$9.51 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -7,302.27% |
| Shareholder Yield | -7,302.27% |
| Earnings Yield | -2,137.95% |
| FCF Yield | -709.62% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $25.50 |
| Price Target Difference | 1,734.53% |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Dec 30, 2025 |
| Split Type | Reverse |
| Split Ratio | 1:18 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |